Big Data Clinical Trials Gene Genome 
Drug Discovery World
JULY 11, 2023
Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. One system that has been especially useful in generating relevant and accurate biological data is the patient- derived xenograft (PDX) model for cancer studies.
Drug Discovery World
SEPTEMBER 6, 2022
DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. billion, compared to $19.9 Cancer is king .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
AUGUST 24, 2023
This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, ”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW.
Drug Discovery World
DECEMBER 27, 2023
Ng is working on critical challenges in clinical trials, specifically in planning and recruitment, and has been building innovative solutions designed to benefit patients and researchers – with a focus on efficiency, transparency and diversity in clinical development. Listen here. Listen here.
Drug Discovery World
FEBRUARY 6, 2024
As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. Automation is also being applied to genomics sample preparation, an area that requires particular robustness and scalability.
Drug Discovery World
FEBRUARY 6, 2023
Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.
pharmaphorum
DECEMBER 8, 2022
The advent of biologic therapies in the 1970s along with the decoding of the human genome in 2003 heralded an explosion in pharmaceutical innovation. This has led to an increase in products coming to market with single‑arm Phase 3 data and surrogate endpoints or Phase 2b data, with planned confirmatory data to be released in the future.
Expert insights. Personalized for you.
40 
Let's personalize your content